PT3072510T - Composições de éster de ácido gordo ómega-3 - Google Patents

Composições de éster de ácido gordo ómega-3

Info

Publication number
PT3072510T
PT3072510T PT16165946T PT16165946T PT3072510T PT 3072510 T PT3072510 T PT 3072510T PT 16165946 T PT16165946 T PT 16165946T PT 16165946 T PT16165946 T PT 16165946T PT 3072510 T PT3072510 T PT 3072510T
Authority
PT
Portugal
Prior art keywords
omega
fatty acid
acid ester
ester compositions
compositions
Prior art date
Application number
PT16165946T
Other languages
English (en)
Inventor
Sancilio Frederick
Cacace Janice
Dahim Mohand
Persicaner Peter
Original Assignee
Micelle Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47998519&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3072510(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Micelle Biopharma Inc filed Critical Micelle Biopharma Inc
Publication of PT3072510T publication Critical patent/PT3072510T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355Tocopherols, e.g. vitamin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024Esters of saccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
PT16165946T 2012-03-30 2013-03-11 Composições de éster de ácido gordo ómega-3 PT3072510T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261618161P 2012-03-30 2012-03-30

Publications (1)

Publication Number Publication Date
PT3072510T true PT3072510T (pt) 2019-08-22

Family

ID=47998519

Family Applications (1)

Application Number Title Priority Date Filing Date
PT16165946T PT3072510T (pt) 2012-03-30 2013-03-11 Composições de éster de ácido gordo ómega-3

Country Status (19)

Country Link
US (9) US9302017B2 (pt)
EP (2) EP3072510B1 (pt)
JP (1) JP6359517B2 (pt)
KR (1) KR102193214B1 (pt)
CN (2) CN104321053A (pt)
AU (1) AU2013240427B2 (pt)
CA (1) CA2867168A1 (pt)
CO (1) CO7121328A2 (pt)
DK (1) DK3072510T3 (pt)
ES (1) ES2741560T3 (pt)
HK (1) HK1204978A1 (pt)
HR (1) HRP20191392T1 (pt)
IL (3) IL249821B (pt)
IN (1) IN2014DN08449A (pt)
MX (1) MX359711B (pt)
MY (1) MY189576A (pt)
PT (1) PT3072510T (pt)
RU (1) RU2633862C2 (pt)
WO (1) WO2013148136A1 (pt)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3578177A1 (en) 2008-09-02 2019-12-11 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
BRPI1011876B1 (pt) 2009-04-29 2020-03-31 Amarin Pharma, Inc. Composições farmacêuticas estáveis compreendendo etilácido eicosapentaenoico (etil-epa) e uso das mesmas para tratar ou prevenir uma doença relacionada ao cardiovascular
NZ624963A (en) 2009-04-29 2016-07-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
CN102625847A (zh) 2009-06-15 2012-08-01 阿马里纳制药公司 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl-c水平的组合物和方法
AU2010298222B2 (en) 2009-09-23 2017-01-05 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
AU2011336856A1 (en) 2010-11-29 2013-07-04 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US20130131170A1 (en) 2011-11-07 2013-05-23 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
KR102153143B1 (ko) 2012-01-06 2020-09-08 옴테라 파마슈티칼스, 인크. 유리 산 형태의 오메가-3 다중불포화 지방산의 dpa-농축 조성물
ES2891473T3 (es) 2012-01-06 2022-01-28 Amarin Pharmaceuticals Ie Ltd Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto
CN104321053A (zh) 2012-03-30 2015-01-28 桑茨利奥&孔帕尼股份有限公司 ω-3脂肪酸酯组合物
SG10201913645RA (en) 2012-06-29 2020-03-30 Amarin Pharmaceuticals Ie Ltd Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
WO2015011724A2 (en) 2013-07-22 2015-01-29 Kms Health Center Pvt Ltd A novel omega -3 fatty acid composition with a plant extract
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
WO2015066512A1 (en) * 2013-10-31 2015-05-07 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
WO2016046680A2 (en) * 2014-09-27 2016-03-31 Mohan M Alapati Compositions and methods for the treatment of liver metabolic diseases
MA40846A (fr) * 2014-10-10 2017-09-05 Sancilio & Company Inc Compositions d'acides gras et d'esters d'acides gras auto-micellisantes, ainsi que leur utilisation dans le traitement d'états pathologiques
CN107427484A (zh) * 2015-01-21 2017-12-01 持田制药株式会社 ω3脂肪酸的自乳化组合物
MA41611A (fr) 2015-02-23 2018-01-02 Omthera Pharmaceuticals Inc Préparations en milli-capsules comprenant des acides gras polyinsaturés libres
DE102015106095A1 (de) * 2015-04-21 2016-10-27 K. D. Pharma Bexbach Gmbh Neue Anwendung von Omega-3-Fettsäure(n)
WO2017033119A1 (en) * 2015-08-25 2017-03-02 Rao M Surya Compositions and methods for the treatment of liver metabolic diseases
CN106692973A (zh) * 2015-11-13 2017-05-24 深圳君圣泰生物技术有限公司 一种组合物及其用途、药物制剂
AU2016370626B2 (en) * 2015-12-18 2020-08-20 Afimmune Limited Compositions comprising 15-HEPE and methods of using the same
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
AU2017232554B2 (en) * 2016-03-16 2020-05-14 Golden Omega Norway As Powders and tablets comprising omega-3 fatty acid derivatives and methods for their production
US11241408B2 (en) 2016-08-12 2022-02-08 Pharmako Biotechnologies Pty Limited Omega-3 compositions and methods relating thereto
AU2017329957B2 (en) 2016-09-21 2020-05-07 Avexxin As Pharmaceutical composition
US10966951B2 (en) 2017-05-19 2021-04-06 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
CN108354919A (zh) * 2017-12-29 2018-08-03 广东海洋大学 一种用于提高抗氧化功能的不饱和脂肪酸组合物及其应用
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
MA51765A (fr) 2018-09-24 2020-12-16 Amarin Pharmaceuticals Ie Ltd Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
US20220096416A1 (en) * 2019-02-01 2022-03-31 Mars, Incorporated Feline food composition
US20230126529A1 (en) 2020-03-12 2023-04-27 Fred D. Sancilio Docosahexaenoic acid and egg yolk containing composition suitable for sickle cell disease treatment
US20230398088A1 (en) * 2020-10-30 2023-12-14 The Trustees Of The University Of Pennsylvania Lipid Prophylactic Brain Injury Treatment
US11986452B2 (en) 2021-04-21 2024-05-21 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513008A (en) 1982-07-30 1985-04-23 The Vinoxen Company, Inc. Virucidal compositions and therapy
US4992476A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Skin cleansing and moisturizing composition and method of using and preparing same
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
AU629915B2 (en) 1989-02-16 1992-10-15 British Technology Group Limited Dispensing device
US5320798A (en) 1993-02-17 1994-06-14 Exxon Chemical Patents, Inc. Method for processing polyolefins at high shear rates
US5585192A (en) 1995-10-02 1996-12-17 Eastman Chemical Company Waterborne polyolefin adhesion promoter
DE69842121D1 (de) * 1997-12-10 2011-03-17 Cyclosporine Therapeutics Ltd Omega-3 fettsäure enthaltende pharmazeutische zusammensetzungen
US6121210A (en) 1998-03-12 2000-09-19 Dap Products Inc. Foamable silicone oil compositions and methods of use thereof
IT1308613B1 (it) * 1999-02-17 2002-01-09 Pharmacia & Upjohn Spa Acidi grassi essenziali nella prevenzione di eventi cardiovascolari.
EP1214059B1 (en) 1999-09-21 2005-05-25 Skyepharma Canada Inc. Surface modified particulate compositions of biologically active substances
NO313076B1 (no) 1999-12-28 2002-08-12 Pronova Biocare As Flytende n¶rings- og/eller nytelsesmiddel og fremgangsmåte for fremstilling derav
KR100441167B1 (ko) 2001-12-27 2004-07-21 씨제이 주식회사 마이크로에멀젼 예비 농축액 조성물
US8729124B2 (en) 2002-03-05 2014-05-20 Pronova Biopharma Norge As Use of EPA and DHA in secondary prevention
AU2003238264B2 (en) 2002-06-18 2009-05-21 Dsm Ip Assets B.V. Stable emulsions of oils in aqueous solutions and methods for producing same
AU2004266502B2 (en) 2002-10-25 2010-09-23 Foamix Pharmaceuticals Ltd. Penetrating pharmaceutical foam
MXPA05004278A (es) 2002-10-25 2005-10-05 Foamix Ltd Espuma cosmetica y farmaceutica.
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
EP1684739A4 (en) 2003-11-12 2006-12-06 Childrens Medical Center TREATMENT AND PREVENTION OF PARENTERAL NUTRITION-RELATED LIVER DISEASE (PN)
SE0303513D0 (sv) 2003-12-19 2003-12-19 Pronova Biocare As Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof
US7919526B2 (en) 2004-03-04 2011-04-05 Htl High-Tech Lipids Ltd. Structured triglycerides and emulsions comprising same
CA2572344A1 (en) 2004-07-01 2006-01-19 Schepens Eye Research Compositions and methods for treating eye disorders and conditions
US8377494B2 (en) 2004-07-22 2013-02-19 Aquanova Ag Concentrates of active agents, such as W-3 fatty acids, and polysorbate
ITRM20040395A1 (it) * 2004-08-03 2004-11-03 Sigma Tau Ind Farmaceuti Composizione comprendente statine e acidi grassi omega 3.
AU2005271407A1 (en) 2004-08-06 2006-02-16 Transform Pharmaceuticals, Inc. Novel fenofibrate formulations and related methods of treatment
JP2008509154A (ja) 2004-08-06 2008-03-27 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド 新規なスタチン薬剤組成物および関連治療方法
CA2577345C (en) * 2004-08-18 2013-02-19 Hiroki Ueshima Jelly composition
JPWO2006022291A1 (ja) 2004-08-27 2008-05-08 千寿製薬株式会社 ドライアイ治療用点眼液
US8324276B2 (en) 2005-01-24 2012-12-04 Pronova Biopharma Norge As Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
JP2008533029A (ja) 2005-03-08 2008-08-21 レリアント ファーマスーティカルズ インコーポレイテッド スタチン及びω−3脂肪酸による治療方法、並びにそれらの複合生成物
US20060223737A1 (en) 2005-03-25 2006-10-05 L'oreal Foaming O/W emulsion and use thereof in cosmetics
US9968120B2 (en) 2006-05-17 2018-05-15 Dsm Nutritional Products Ag Homogenized formulations containing microcapsules and methods of making and using thereof
JP2009510115A (ja) 2005-09-29 2009-03-12 アリーナ ファーマシューティカルズ, インコーポレイテッド 5−ht2aセロトニン受容体に関連する疾患の治療に有用な5−ht2aセロトニン受容体モジュレーターの薬学的組成物
US20070104779A1 (en) 2005-11-07 2007-05-10 Rongen Roelof M Treatment with omega-3 fatty acids and products thereof
US8962682B2 (en) 2005-11-11 2015-02-24 Mochida Pharmaceutical Co., Ltd. Jelly composition
CA2629091A1 (en) 2005-11-22 2007-05-31 Nestec S.A. Oil-in-water emulsion and its use for the delivery of functionality
CA2634139C (en) 2005-12-20 2015-06-23 Cenestra, Llc. Omega 3 fatty acid formulations
US20080058418A1 (en) * 2006-09-06 2008-03-06 The Coca-Cola Company Stable polyunsaturated fatty acid emulsions and methods for inhibiting, suppressing, or reducing degradation of polyunsaturated fatty acids in an emulsion
CN101553136A (zh) * 2006-09-06 2009-10-07 可口可乐公司 稳定的多不饱和脂肪酸乳液及用于防止、抑制或降低多不饱和脂肪酸在乳液中降解的方法
US20080102131A1 (en) 2006-10-31 2008-05-01 Kaneka Corporation Particulate composition comprising bioactive substance and method of producing the same
US20080306154A1 (en) 2006-11-03 2008-12-11 My Svensson Treatment and prevention of major adverse cardiovascular events or major coronary evens by administering Omega-3 fatty acids
US20090011012A1 (en) 2007-07-06 2009-01-08 Baum Seth J Fatty acid compositions and methods of use
US20090182049A1 (en) 2008-01-16 2009-07-16 Joar Arild Opheim Pharmaceutical Composition and Method for Treating Hypertriglyceridemia and Hypercholesterolemia in Humans
GB0813599D0 (en) * 2008-07-24 2008-09-03 Pharma Marine As Method
US20100062057A1 (en) 2008-09-10 2010-03-11 Pronova BioPharma Norge AS. Formulation
CN101380358B (zh) 2008-10-14 2012-12-19 沈阳药科大学 精制紫苏籽油脂肪乳注射液及制备工艺
WO2010103402A1 (en) 2009-03-09 2010-09-16 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture comprising epa and dha in free acid form and a surfactant, and methods and uses thereof
US20110071090A1 (en) * 2009-03-11 2011-03-24 Stable Solutions Llc Method of mitigating adverse drug events using omega-3-fatty acids as a parenteral therapeutic drug vehicle
WO2010118761A1 (en) 2009-04-17 2010-10-21 Eolas Science Limited Compositions rich in omega-3 fatty acids with a low content in phytanic acid
NZ624963A (en) 2009-04-29 2016-07-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
WO2010134614A1 (ja) * 2009-05-22 2010-11-25 持田製薬株式会社 ω3脂肪酸の自己乳化組成物
US9480645B2 (en) 2009-06-02 2016-11-01 Abbott Medical Optics Inc. Omega-3 oil containing ophthalmic emulsions
US20110045050A1 (en) 2009-08-24 2011-02-24 Atrium Medical Corporation Nanoemulsion formulations for direct delivery
WO2011047259A1 (en) 2009-10-16 2011-04-21 Glaxosmithkline Llc Compositions
US9370493B2 (en) * 2009-10-23 2016-06-21 Pronova Biopharma Norge As Coated capsules and tablets of a fatty acid oil mixture
CA2780486C (en) 2009-11-10 2018-01-02 MyCell Holdings Limited Stabilized formulations of fatty acids
EP2613766A4 (en) 2010-09-08 2014-04-09 Pronova Biopharma Norge As COMPOSITIONS COMPRISING AN OIL MIXTURE CONSISTING OF FATTY ACIDS COMPRISING EPA AND DHA AS FREE ACID, SURFACTANT AND STATIN
WO2012032414A2 (en) 2010-09-08 2012-03-15 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture, a surfactant, and a statin
EP2613767A4 (en) * 2010-09-08 2014-03-19 Pronova Biopharma Norge As COMPOSITIONS COMPRISING FATTY ACID OIL MIXTURE, FREE FATTY ACID, TENSID AND STATINE
WO2012037311A1 (en) 2010-09-17 2012-03-22 Maine Natural Health, Inc. Compositions containing omega-3 oil and uses thereof
US9415035B2 (en) 2010-09-17 2016-08-16 Maine Natural Health Company, Inc. Compositions containing omega-3 oil with an anti-inflammatory agent and uses thereof
WO2013123466A1 (en) 2012-02-16 2013-08-22 Brightside Innovations, Inc. Dietary and nutritional compositions and methods of use
CN104321053A (zh) 2012-03-30 2015-01-28 桑茨利奥&孔帕尼股份有限公司 ω-3脂肪酸酯组合物

Also Published As

Publication number Publication date
AU2013240427B2 (en) 2017-08-03
EP3072510B1 (en) 2019-05-08
RU2014141406A (ru) 2016-05-20
IN2014DN08449A (pt) 2015-05-08
CN104321053A (zh) 2015-01-28
CN109966279A (zh) 2019-07-05
US20150328153A1 (en) 2015-11-19
US20150328324A1 (en) 2015-11-19
EP2830602A1 (en) 2015-02-04
US9364561B2 (en) 2016-06-14
DK3072510T3 (da) 2019-08-12
US20140348930A1 (en) 2014-11-27
CO7121328A2 (es) 2014-11-20
IL249821B (en) 2019-04-30
KR102193214B1 (ko) 2020-12-18
US20150328177A1 (en) 2015-11-19
JP2015514083A (ja) 2015-05-18
CA2867168A1 (en) 2013-10-03
US20150328178A1 (en) 2015-11-19
HRP20191392T1 (hr) 2019-12-27
RU2633862C2 (ru) 2017-10-18
ES2741560T3 (es) 2020-02-11
MX2014011596A (es) 2015-07-06
US9364558B2 (en) 2016-06-14
MX359711B (es) 2018-10-08
MY189576A (en) 2022-02-17
IL234814A (en) 2017-11-30
US20140348929A1 (en) 2014-11-27
US9364559B2 (en) 2016-06-14
US9364560B2 (en) 2016-06-14
US9370585B2 (en) 2016-06-21
US9302017B2 (en) 2016-04-05
US9302016B2 (en) 2016-04-05
JP6359517B2 (ja) 2018-07-18
KR20140145597A (ko) 2014-12-23
WO2013148136A1 (en) 2013-10-03
US20150328325A1 (en) 2015-11-19
IL249821A0 (en) 2017-02-28
US9364562B2 (en) 2016-06-14
AU2013240427A1 (en) 2014-09-25
EP2830602B1 (en) 2020-10-21
US20150328327A1 (en) 2015-11-19
US9375490B2 (en) 2016-06-28
HK1204978A1 (en) 2015-12-11
US20150328326A1 (en) 2015-11-19
EP3072510A1 (en) 2016-09-28

Similar Documents

Publication Publication Date Title
IL249821A0 (en) Preparations of omega 3 fatty acid esters
IL266231B (en) Compounds of omega-3 polyunsaturated fatty acids are enriched in dpa in the form of fat in the free acid phase
HK1206248A1 (en) Compositions of statins and omega-3 fatty acids -3
EP3735963C0 (en) SELF-EMULSIFYING COMPOSITION OF OMEGA-3 FATTY ACIDS
SG11201600337PA (en) SELF-EMULSIFYING COMPOSITION OF ω-3 FATTY ACID
HK1206596A1 (en) Pharmaceutical compositions comprising fatty acid esters
EP2861227A4 (en) OMEGA-3 PENTAIC ACID COMPOSITIONS AND METHODS OF USE
IL228516A (en) A compound for oral administration containing an omega-3 fatty acid ester and rosovastatin
HK1198515A1 (en) Fatty acid compositions
EP2809317A4 (en) FATTY ACIDS AS ANTI-INFLAMMATORY AGENTS
HK1206279A1 (en) Pharmaceutical compositions comprising glycerol esters
ZA201302760B (en) Novel omega-3 and omega-6 fatty acid compositions and uses thereof
EP2825057B8 (en) Oxidixable fatty acid composition delivery form
PL2860211T3 (pl) Preparaty estrów kwasu fosforowego o obniżonej higroskopijności
EP2726086A4 (en) COMPOSITIONS CONTAINING FATTY NITROACIDS
EP2845585A4 (en) COMPOSITION OF FATTY ACID ESTERS OF TRHEHALOSIS
EP2929041A4 (en) PENTAENOIC ACID COMPOSITIONS OF OMEGA-3 AND ASSOCIATED METHODS OF USE
GB201412395D0 (en) Fatty acid ester compositions for use as emollients
HK1185806A1 (zh) 含有多不飽和脂肪酸的組合物